CCN2 and chronic kidney disease: SRT1720 (N-[2-[3-(piperazin-1-ylmethyl) imidazo [2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide), an SIRT1 activator, has an essential role in preventing the progression of CKD by transforming growth factor-beta1 (TGF-beta1)/connective tissue growth factor (CTGF) pathway inhibition in UUO-induced tubulointerstitial fibrosis [135] (Table 1).